AZD8055

For research use only. Not for use in humans.

目录号：S1555

CAS No. 1009298-09-2

AZD8055是一种新型的，ATP竞争性mTOR抑制剂，在MDA-MB-468 细胞中IC50为0.8 nM，与作用于PI3K亚型和ATM/DNA-PK相比，具有优异的选择性（约1000倍）。AZD8055可诱导半胱天冬酶依赖的凋亡和自噬。Phase 1。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1265.49	现货
5mg	RMB 712.53	现货
10mg	RMB 988.31	现货
50mg	RMB 3048.72	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的AZD8055发表文献171篇：

Nature, 2019, 10.1038/s41586-019-1607-3

PubMed: 31578521 ( click the link to review the publication )

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Cell Stem Cell, 2018, 22(3):369-383

PubMed: 29499153 ( click the link to review the publication )

Nat Med, 2017, 23(2):200-212

PubMed: 28067899 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):177-190

PubMed: 27939219 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):255-63

PubMed: 25564516 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):245-54

PubMed: 25564517 ( click the link to review the publication )

Cancer Cell, 2015, 27(1):97-108

PubMed: 25544637 ( click the link to review the publication )

Cancer Cell, 2015, 27(4):533-46

PubMed: 25873175 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4684

PubMed: 32943635 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107810

PubMed: 32579936 ( click the link to review the publication )

Eur J Cancer, 2020, 126:93-103

PubMed: 31927215 ( click the link to review the publication )

J Bone Miner Res, 2020, 10.1002/jbmr.4176

PubMed: 32916025 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 9;39(1):107

PubMed: 32517736 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Front Immunol, 2020, 11:572960

PubMed: 33013932 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.1131.2019

PubMed: 32371585 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(3):882-894

PubMed: 31879363 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(19):19022-19044

PubMed: 33044945 ( click the link to review the publication )
J Cancer, 2020, 15;11(12):3492-3501

PubMed: 32284745 ( click the link to review the publication )

Sci Rep, 2020, 4;10(1):4025

PubMed: 32132574 ( click the link to review the publication )

J Biol Chem, 2020, 22;295(21):7418-7430

PubMed: 32312748 ( click the link to review the publication )

Cell Cycle, 2020, 1-15

PubMed: 33064959 ( click the link to review the publication )

Biosci Rep, 2020, 30;40(4):BSR20200905

PubMed: 32285908 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 23;S0006-291X(20)30951-7

PubMed: 32456793 ( click the link to review the publication )

G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

Kaohsiung J Med Sci, 2020, 10.1002/kjm2.12319

PubMed: 33174370 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3627

PubMed: 32686664 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):724

PubMed: 32758183 ( click the link to review the publication )

Nat Med, 2020, 10.1038/s41591-020-0986-1

PubMed: 32719489 ( click the link to review the publication )

J Cell Biol, 2020, 219(2)

PubMed: 31914171 ( click the link to review the publication )

J Invest Dermatol, 2020, S0022-202X(20)31981-3

PubMed: 32805217 ( click the link to review the publication )

Int Immunopharmacol, 2020, 81:106241

PubMed: 32058927 ( click the link to review the publication )

Cell Rep, 2020, 32(3):107933

PubMed: 32697996 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12673

PubMed: 32191822 ( click the link to review the publication )

Cancer, 2020, 10.1002/cncr.33071

PubMed: 32767682 ( click the link to review the publication )

Mol Cell, 2019, 10.1016/j.molcel.2019.10.016

PubMed: 31733992 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1660545

PubMed: 31462148 ( click the link to review the publication )

Autophagy, 2019, 15(3):543-557

PubMed: 30269645 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(21):6429-6442

PubMed: 31439581 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(16):5107-5121

PubMed: 31164374 ( click the link to review the publication )

Curr Biol, 2019, 29(5):737-749

PubMed: 30773367 ( click the link to review the publication )

Cell Rep, 2019, 27(12):3696-3708.e5

PubMed: 31216485 ( click the link to review the publication )
Sci Signal, 2019, 12(612)

PubMed: 31848319 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31627299 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(3):366-377

PubMed: 30661989 ( click the link to review the publication )

Curr Biol, 2019, 29(5):737-749

PubMed: 30773367 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(9):1922-1937

PubMed: 31598395 ( click the link to review the publication )

Sci Rep, 2019, 9(1):30

PubMed: 30631106 ( click the link to review the publication )

Sci Rep, 2019, 9(1):9805

PubMed: 31285446 ( click the link to review the publication )

Cancer Gene Ther, 2019, 10.1038/s41417-019-0117-7

PubMed: 31257364 ( click the link to review the publication )

Biochem J, 2019, 476(20):3081-3107

PubMed: 31665227 ( click the link to review the publication )

Front Physiol, 2019, 10:167

PubMed: 30873046 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:5196028

PubMed: 31223619 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):21-36

PubMed: 30831322 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Nat Cell Biol, 2018, 20(4):465-478

PubMed: 29593330 ( click the link to review the publication )

Cancer Res, 2018, 78(12):3176-3189

PubMed: 29661831 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1063

PubMed: 30337536 ( click the link to review the publication )

J Mol Cell Biol, 2018, 10(4):331-340

PubMed: 29190376 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 39(8):1338-1346

PubMed: 29345254 ( click the link to review the publication )

Front Genet, 2018, 9:690

PubMed: 30671083 ( click the link to review the publication )

Cell Signal, 2018, 44:127-137

PubMed: 29329780 ( click the link to review the publication )

PLoS One, 2018, 13(8):e0200725

PubMed: 30067771 ( click the link to review the publication )

Med Sci Monit, 2018, 24:2735-2743

PubMed: 29720580 ( click the link to review the publication )

Oncol Lett, 2018, 16(4):4561-4566

PubMed: 30214591 ( click the link to review the publication )
J Exp Med, 2018, 215(1):159-175

PubMed: 29141866 ( click the link to review the publication )

Oncol Lett, 2018, 16(1):632-642

PubMed: 29928450 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1090

PubMed: 29061961 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2207

PubMed: 29263324 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

Cell Syst, 2017,

PubMed: 28017544 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Cell Rep, 2017, 20(10):2341-2356

PubMed: 28877469 ( click the link to review the publication )

Oncogene, 2017, 36(15):2074-2084

PubMed: 27748760 ( click the link to review the publication )

Oncogene, 2017, 36(26):3651-3660

PubMed: 28192408 ( click the link to review the publication )

PLoS Pathog, 2017, 13(4):e1006344

PubMed: 28414774 ( click the link to review the publication )

Cell Commun Signal, 2017, 10.1186/s12964-017-0164-3

PubMed: 28143584 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2017, 1864(10):1554-1565

PubMed: 28641977 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181243

PubMed: 28704514 ( click the link to review the publication )

Anticancer Res, 2017, 37(3):1083-1090

PubMed: 28314268 ( click the link to review the publication )

Oncotarget, 2017, 8(4):5992-6002

PubMed: 27863413 ( click the link to review the publication )

Oncotarget, 2017, 8(1):979-987

PubMed: 27894090 ( click the link to review the publication )

Oncotarget, 2017, 8(25):41422-41431

PubMed: 28507282 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(5):527-39

PubMed: 27043084 ( click the link to review the publication )

Genome Biol, 2016, 17(1):149

PubMed: 27380875 ( click the link to review the publication )

Nat Chem Biol, 2016, 12(1):22-8

PubMed: 26595461 ( click the link to review the publication )

EMBO J, 2016, 35(17):1902-22

PubMed: 27481935 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Mol Oncol, 2016, 10(4):538-52

PubMed: 26686971 ( click the link to review the publication )
Aging (Albany NY), 2016, 8(2):231-44

PubMed: 26851731 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(12):3535-3551

PubMed: 28077803 ( click the link to review the publication )

Sci Rep, 2016,

PubMed: 27849011 ( click the link to review the publication )

J Biol Chem, 2016, 291(12):6262-71

PubMed: 26755732 ( click the link to review the publication )

Front Plant Sci, 2016, 7:1746

PubMed: 27917191 ( click the link to review the publication )

Cell Signal, 2016, 28(4):284-93

PubMed: 26795954 ( click the link to review the publication )

PLoS One, 2016, 11(4):e0154564

PubMed: 27128484 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(4):1515-20

PubMed: 27565731 ( click the link to review the publication )

Int J Endocrinol, 2016, 2016:5286972

PubMed: 27990160 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Autophagy, 2015, 11(2):285-97

PubMed: 25801301 ( click the link to review the publication )

Cancer Res, 2015, 75(20):4398-406

PubMed: 26359452 ( click the link to review the publication )

Cell Rep, 2015, 11(3):446-59

PubMed: 25865887 ( click the link to review the publication )

J Hematol Oncol, 2015,

PubMed: 26515759 ( click the link to review the publication )

Sci Signal, 2015, 8(375):ra42

PubMed: 25943352 ( click the link to review the publication )

J Med Chem, 2015, 58(16):6559-73

PubMed: 26237138 ( click the link to review the publication )

Clin Sci, 2015, 128(8):517-26

PubMed: ( click the link to review the publication )

J Cancer, 2015, 6(12):1195-205

PubMed: 26535060 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: 25232030 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: 25582703 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074/jbc.C114.627778

PubMed: 25833948 ( click the link to review the publication )
Biochem J, 2015, 465(2):227-38

PubMed: 25353634 ( click the link to review the publication )

J Chromatogr A, 2015, 1388:267-73

PubMed: 25725958 ( click the link to review the publication )

J Chromatogr A, 2015, 1388:267-73

PubMed: ( click the link to review the publication )

Proteomics, 2015, 10.1002/pmic.201400586

PubMed: 25764225 ( click the link to review the publication )

Cancer Biol Ther, 2015,

PubMed: 25692408 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0143357

PubMed: 26580203 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0131400

PubMed: 26148118 ( click the link to review the publication )

Clin Sci (Lond), 2015, 128(8):517-26

PubMed: 25428582 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Cell Signal, 2015, 27(11):2191-200

PubMed: 26210887 ( click the link to review the publication )

J Clin Invest, 2014, 10.1172/JCI73935

PubMed: 25415435 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Autophagy, 2014, 10(6):1120-36

PubMed: 24879157 ( click the link to review the publication )

Leukemia, 2014, 28(5):1092-102

PubMed: 24135829 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Res, 2014, 74(14):3947-58

PubMed: 24986516 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(22):5756-67

PubMed: 25316808 ( click the link to review the publication )

Int J Cancer, 2014, 10.1002/ijc.28880

PubMed: 24706460 ( click the link to review the publication )

Antioxid Redox Sign, 2014, 20(9):1382-95

PubMed: 24063548 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(6):1429-38

PubMed: 24643969 ( click the link to review the publication )

Am J Cancer Res, 2014,

PubMed: 25520871 ( click the link to review the publication )

Am J Cancer Res, 2014, 4(6):824-837

PubMed: ( click the link to review the publication )

Mol Cell Biol, 2014, 34(22):4088-103

PubMed: 25182533 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )
Mol Reprod Dev, 2014, 81(7):655-65

PubMed: 24753052 ( click the link to review the publication )

Oncol Rep, 2014, 31(2):649-56

PubMed: 24297300 ( click the link to review the publication )

PLoS One, 2014, 9(12):e113555

PubMed: 25460003 ( click the link to review the publication )

Oncotarget, 2014,

PubMed: 25277205 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10732-44

PubMed: 25313141 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10503-17

PubMed: 25361177 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6015-27

PubMed: 24970798 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Blood, 2013, 121(18):3619-30

PubMed: 23444404 ( click the link to review the publication )

EMBO J, 2013, 28;32(17):2377-91

PubMed: 23921550 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )

Am J Transplant, 2013, 13(8):2035-43

PubMed: 23841834 ( click the link to review the publication )

Sci Signal, 2013, 6(271):ra25

PubMed: 23592840 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(1):37-48

PubMed: 24233399 ( click the link to review the publication )

Mol Cancer Ther, 2013,

PubMed: 23615631 ( click the link to review the publication )

Mol Oncol, 2013, 33:404-18

PubMed: 24444656 ( click the link to review the publication )

J Hypertens, 2013, 31(2):303-11

PubMed: 23303355 ( click the link to review the publication )

J Biol Chem, 2013, 288(49):35287-96

PubMed: 24133218 ( click the link to review the publication )

Mol Biol Cell, 2013, 24(23):3736-45

PubMed: 24088573 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56567

PubMed: 23451056 ( click the link to review the publication )

Onco Targets Ther, 2013, 6:1373-84

PubMed: 24124380 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 440(4):701-6

PubMed: 24103749 ( click the link to review the publication )

Oncol Lett, 2013, 5(2):717-721

PubMed: 23420667 ( click the link to review the publication )
Autophagy, 2012, 9(1):74-92

PubMed: 23196898 ( click the link to review the publication )

Exp Neurol, 2012, 233(2):799-806

PubMed: 22177999 ( click the link to review the publication )

Biochem Pharmacol, 2012, 83(9):1183-94

PubMed: 22305748 ( click the link to review the publication )

产品安全说明书

mTOR抑制剂选择性比较

生物活性

产品描述

特性

AZD8055是第一种抑制两种类型mTOR蛋白的药物，被认为可能比之前mTOR抑制剂更有效。

靶点

mTOR (truncated) ^[1] (MDA-MB-468 cells)	mTOR (full length) ^[1] (MDA-MB-468 cells)
0.13 nM	0.8 nM

体外研究

AZD8055作用于所有 PI3K亚型 (α, β, γ, δ) 和其他近PI3K激酶家族(ATM和DNA-PK)显示出低活性。AZD8055抑制mTORC1(p70S6K 和4E-BP1) ，mTORC2 (AKT) 和下游蛋白的磷酸化。AZD8055完全抑制4E-BP1抗Rapamycin 的T37/46 磷酸化位点, 导致明显抑制cap-dependent 转译作用。AZD8055有效抑制U87MG, A549和H838 细胞增殖， IC50分别为53, 50，和20 nM。AZD8055作用于H838和A549细胞，也诱导自体吞噬和增加LC3-II 水平。^[1] AZD8055降低白血病细胞增殖和细胞周期进展, 降低白血病祖细胞的无性系生长，且在白血病细胞中诱导caspase依赖的细胞凋亡，但是作用于正常未成熟的CD34+ 细胞时不会产生这种诱导作用。^[2] AZD8055 抑制儿科临床前期测试计划(PPTP)细胞系，IC50 为24.7 nM，且在EFS 分布时诱导产生明显区别。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
LU-139	M1;WV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3L2c2lEPTB;MD6wNlM{OSEQvF2=	MWjTRW5ITVJ?
NCI-H720	M{LTW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTBwMEK5N\|gh\|ryP	Moj3V2FPT0WU
KARPAS-45	Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1ziW2lEPTB;MD6wN\|M4OSEQvF2=	MV7TRW5ITVJ?
EW-3	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrmTmxKSzVyPUCuNFQxPTZizszN	NF\KSGpUSU6JRWK=
SBC-1	M2fwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnm0TWM2OD1yLkC0OVgyKM7:TR?=	MYPTRW5ITVJ?
NCI-H209	M1PlVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3p[21UUUN3ME2wMlA2PDV\|IN88US=>	M1z6cXNCVkeHUh?=
EoL-1-cell	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELRdVZKSzVyPUCuNFY2PjlizszN	MnO4V2FPT0WU
H9	MojrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\PU41KSzVyPUCuNFY3QTJizszN	NICyOYxUSU6JRWK=
AN3-CA	NVjLXWJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvHdolKSzVyPUCuNFc6PTFizszN	NXH1RYFCW0GQR1XS
HH	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHv5O4xKSzVyPUCuNFgxODlizszN	M1zSWHNCVkeHUh?=
KU812	M331VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfPNFVKSzVyPUCuNFgxPDNizszN	M33idnNCVkeHUh?=
DU-4475	M2q5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TJT2lEPTB;MD6wPFA1PyEQvF2=	MV3TRW5ITVJ?
CTV-1	NV\EUFNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTBwMEi2OFEh\|ryP	MX;TRW5ITVJ?
BV-173	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTBwMEmwOlEh\|ryP	MnLOV2FPT0WU
ES5	NHjqPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTBwMEmzOUDPxE1?	M{HMNXNCVkeHUh?=
G-402	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vtcGlEPTB;MD6wPVk5KM7:TR?=	M4DCe3NCVkeHUh?=
MV-4-11	Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTBwMUCzOFch\|ryP	M13sVnNCVkeHUh?=
NB69	M4XGPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzUTWM2OD1yLkGzOUDPxE1?	MYHTRW5ITVJ?
EGI-1	NF;SeI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{j0PWlEPTB;MD6xN\|U{OSEQvF2=	NGnqUXRUSU6JRWK=
EW-18	NH\aeGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTBwMUSwO\|Mh\|ryP	MVnTRW5ITVJ?
ME-180	NEThR\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPPTWM2OD1yLkG0OlgyKM7:TR?=	MonhV2FPT0WU
D-283MED	NGGweIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHzoflBKSzVyPUCuNVQ4OjNizszN	MlK2V2FPT0WU
NB14	M4qxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fDS2lEPTB;MD6xOlQ1PyEQvF2=	NF\u[\|JUSU6JRWK=
Ramos-2G6-4C10	Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrEVmFZUUN3ME2wMlE3QTh\|IN88US=>	MXzTRW5ITVJ?
NBsusSR	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7pVXpKSzVyPUCuNVcxOTlizszN	NGG2[lNUSU6JRWK=
LAMA-84	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4LFc2lEPTB;MD6xPFA{OiEQvF2=	M3nYenNCVkeHUh?=
NCI-H1581	NFvyVVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGizU\|ZKSzVyPUCuNVg6PjZizszN	MYLTRW5ITVJ?
A204	NF3GR5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTBwMUi5O{DPxE1?	NH2xRoJUSU6JRWK=
A549	NXj5[XZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jIdWlEPTB;MD6xPVU2KM7:TR?=	M{O3[HNCVkeHUh?=
CAL-51	NXHId2VHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;TNGlEPTB;MD6xPVY2OSEQvF2=	M4jWT3NCVkeHUh?=
NKM-1	M{fMXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTBwMkCwNlkh\|ryP	NVHF[2tNW0GQR1XS
LoVo	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTBwMkCyNFIh\|ryP	MYLTRW5ITVJ?
HAL-01	NH7nSHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPPSHI3UUN3ME2wMlIxOjl5IN88US=>	MUHTRW5ITVJ?
HCC2218	M37lfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M330N2lEPTB;MD6yNFY5QCEQvF2=	MnjlV2FPT0WU
BEN	NV\JSJlqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXuZXNKSzVyPUCuNlEzQTNizszN	NWrhUXZDW0GQR1XS
LC-2-ad	M2rhVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\Be5djUUN3ME2wMlIzODh2IN88US=>	NYixZWJDW0GQR1XS
LXF-289	NEGwe5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTBwMkWwOFEh\|ryP	MV7TRW5ITVJ?
HGC-27	NUTQ[HBHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjhT4ZZUUN3ME2wMlI3PDF2IN88US=>	MX\TRW5ITVJ?
LK-2	NIPUVWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHTkXXdKSzVyPUCuNlY5OjRizszN	NGTYWXVUSU6JRWK=
CTB-1	NYHF[3JjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTBwMkeyNVUh\|ryP	MnjZV2FPT0WU
697	NVnyd\|JlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jjVGlEPTB;MD6yO\|M3PyEQvF2=	MnvpV2FPT0WU
ES7	M{\We2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPqTWM2OD1yLkK3N\|g{KM7:TR?=	NUHMNVFyW0GQR1XS
MG-63	NXfFVIlXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTBwMke0NFch\|ryP	NYSzUXhsW0GQR1XS
T47D	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXriSoVUUUN3ME2wMlI4PDd3IN88US=>	MVjTRW5ITVJ?
RPMI-8226	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTBwMki1PFkh\|ryP	MlHJV2FPT0WU
NCI-H292	MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\6RVhKSzVyPUCuNlkyPjRizszN	NVfvfllxW0GQR1XS
HT	MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHXtW4xKSzVyPUCuNlk{QCEQvF2=	M3XGS3NCVkeHUh?=
A3-KAW	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTBwMkm3OEDPxE1?	NGDFS49USU6JRWK=
LB2241-RCC	M4P0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHLWFRKSzVyPUCuN\|AyQThizszN	NWnUelR[W0GQR1XS
BB65-RCC	Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTBwM{C4NFUh\|ryP	NEPGVIdUSU6JRWK=
G-401	Moj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULQRXFvUUN3ME2wMlMxQTh4IN88US=>	NXzmOXRWW0GQR1XS
TYK-nu	MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDxTWM2OD1yLkOxPFY1KM7:TR?=	NX7QTZR5W0GQR1XS
NCI-SNU-1	NYDIOGdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFLlUVlKSzVyPUCuN\|I{OzFizszN	NV[1UItqW0GQR1XS
CHL-1	NVLNW48yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzhN\|RKSzVyPUCuN\|I4ODNizszN	M3fPbHNCVkeHUh?=
P30-OHK	NIq1SINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHRTWM2OD1yLkOyO\|A2KM7:TR?=	MUXTRW5ITVJ?
PA-1	MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTBwM{O2NVkh\|ryP	MYTTRW5ITVJ?
LB1047-RCC	M2\1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\zTWM2OD1yLkO0NFQ4KM7:TR?=	NGP5dHhUSU6JRWK=
EM-2	NGSzVINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGX6UFBKSzVyPUCuN\|QyQDhizszN	NYLZWFVrW0GQR1XS
VA-ES-BJ	NF65eY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFP4WZhKSzVyPUCuN\|QzPjhizszN	M{nWWnNCVkeHUh?=
NCI-H520	NGm3UHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37zUmlEPTB;MD6zOFg{PCEQvF2=	M4\pdHNCVkeHUh?=
ECC10	Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\ZVGdNUUN3ME2wMlM2ODN3IN88US=>	NHLMdWxUSU6JRWK=
LNCaP-Clone-FGC	NWXjd4J3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vVemlEPTB;MD6zOVMyPCEQvF2=	NYjsVHZlW0GQR1XS
ES8	NGjk[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTBwM{[1OVMh\|ryP	MX7TRW5ITVJ?
HuO-3N1	MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvidHJKSzVyPUCuN\|g{PzlizszN	MXjTRW5ITVJ?
L-363	NVTDSmJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTqeZMzUUN3ME2wMlM6ODJ4IN88US=>	NVvRRVl2W0GQR1XS
SK-LU-1	NVrBNplTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XtNWlEPTB;MD6zPVIxQCEQvF2=	M{TxXXNCVkeHUh?=
MCF7	Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEX4cpRKSzVyPUCuOFA2OyEQvF2=	M4P1NXNCVkeHUh?=
HuO9	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3hTFFKSzVyPUCuOFA3PjdizszN	NUWxT3hvW0GQR1XS
BHT-101	MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojpTWM2OD1yLkSwO\|g4KM7:TR?=	M2rSSnNCVkeHUh?=
MZ2-MEL	NYXBZ\|RyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TWW2lEPTB;MD60NFg5OiEQvF2=	NI\xNnVUSU6JRWK=
NOS-1	NWPITlVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLTcGFKSzVyPUCuOFExPzRizszN	NHjRd\|ZUSU6JRWK=
NEC8	MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYm0NodsUUN3ME2wMlQyPjl3IN88US=>	NULQfIx[W0GQR1XS
COR-L88	Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTBwNEKyOlch\|ryP	NXjmVlhzW0GQR1XS
MFM-223	MlvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTBwNEK2NVch\|ryP	NX\PUVc3W0GQR1XS
HSC-3	M374dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTBwNEK5NFgh\|ryP	MmDOV2FPT0WU
OVCAR-5	NFXaR2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPTV5pxUUN3ME2wMlQzQTN\|IN88US=>	MnHHV2FPT0WU
MFE-280	MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1n1OWlEPTB;MD60N\|A{OiEQvF2=	NXfm[JRMW0GQR1XS
KP-N-YS	NE\lb4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTBwNEOwO{DPxE1?	M4r5U3NCVkeHUh?=
EPLC-272H	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV34O2NyUUN3ME2wMlQ{ODd5IN88US=>	MnLWV2FPT0WU
KE-37	M4fNbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPXTWM2OD1yLkSzNlQ4KM7:TR?=	NGriWlFUSU6JRWK=
HuH-7	MmPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPFTWM2OD1yLkSzN\|czKM7:TR?=	MVHTRW5ITVJ?
CHP-212	MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mly4TWM2OD1yLkSzOlk4KM7:TR?=	M3voUnNCVkeHUh?=
SK-MES-1	NWPWc29ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvIbVJKSzVyPUCuOFM5PDhizszN	M{fHRnNCVkeHUh?=
SJSA-1	M3jaN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4KzXmlEPTB;MD60OFU2PCEQvF2=	NXvEXJNKW0GQR1XS
QIMR-WIL	M4XEVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWH1cYRIUUN3ME2wMlQ2OTVizszN	NGHT[ZhUSU6JRWK=
ES4	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrtWWhKSzVyPUCuOFU{OzZizszN	NFLvdXdUSU6JRWK=
TI-73	NI\jbYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTBwNEW2PFYh\|ryP	M4jZUXNCVkeHUh?=
COLO-684	NYLkTII6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jmcWlEPTB;MD60OVczPiEQvF2=	MkPpV2FPT0WU
GCIY	M4XmNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mny3TWM2OD1yLkS1O\|U1KM7:TR?=	MmnrV2FPT0WU
JVM-3	NXfxVW9YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTBwNE[yPVIh\|ryP	NYLMeIhSW0GQR1XS
MPP-89	NXThWlEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnfxTWM2OD1yLkS2PVQ4KM7:TR?=	NUfqb244W0GQR1XS
M14	NUDTTFU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\pTWM2OD1yLkS3NVch\|ryP	M4LjfHNCVkeHUh?=
SW962	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\XTWM2OD1yLkS3NVkh\|ryP	NUHob\|d6W0GQR1XS
VM-CUB-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PDZWlEPTB;MD60O\|I5PiEQvF2=	NFjhbIFUSU6JRWK=
A101D	NFjKb2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXXx[GdTUUN3ME2wMlQ5QTZ6IN88US=>	MVjTRW5ITVJ?
DB	NGXqV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHBOZQzUUN3ME2wMlUxODJzIN88US=>	NHnJV4tUSU6JRWK=
KNS-62	NVnIPYZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnzRo57UUN3ME2wMlUxPTZ6IN88US=>	NG\VXXFUSU6JRWK=
NCI-H460	NXfmOW1rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYT3PZZzUUN3ME2wMlUxPTl5IN88US=>	MmjtV2FPT0WU
MDA-MB-361	M2TTSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnVTWM2OD1yLkWwPFch\|ryP	M37BXXNCVkeHUh?=
DOK	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTBwNUGzN\|Mh\|ryP	NGjuPFBUSU6JRWK=
CAL-39	Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXnu[ZNyUUN3ME2wMlUzOjZ6IN88US=>	NU\re412W0GQR1XS
HT-1080	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTBwNUK1OFMh\|ryP	NX;nVJVOW0GQR1XS
GR-ST	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17sUWlEPTB;MD61N\|AyPSEQvF2=	M2rkZ3NCVkeHUh?=
J-RT3-T3-5	M4W5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXoWWNLUUN3ME2wMlU{OTl3IN88US=>	MkHYV2FPT0WU
NCI-H1793	NIHiSopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTBwNUO0OFch\|ryP	M1fTenNCVkeHUh?=
NCI-H1355	NHTlOXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGDCeVJKSzVyPUCuOVM5PzhizszN	MnroV2FPT0WU
YH-13	NX\vZoRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TzO2lEPTB;MD61OFk{QCEQvF2=	MXfTRW5ITVJ?
LOXIMVI	NELob2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M336UmlEPTB;MD61OVEzOyEQvF2=	MX3TRW5ITVJ?
ES1	M3zORWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLrWpB6UUN3ME2wMlU2PTF6IN88US=>	MWrTRW5ITVJ?
GAMG	NH31OppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPROmFPUUN3ME2wMlU2PjV6IN88US=>	M{TRWHNCVkeHUh?=
SK-MEL-28	MmPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LtV2lEPTB;MD61OVkyKM7:TR?=	MkXuV2FPT0WU
KG-1	MkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDsTWM2OD1yLkW2PFg1KM7:TR?=	NYGwUFVsW0GQR1XS
HOS	NEnhW\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYK2W416UUN3ME2wMlU4OTl{IN88US=>	MYXTRW5ITVJ?
PANC-08-13	NGmwfHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTBwNUezPFkh\|ryP	MmDuV2FPT0WU
SW780	NIHVTm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{W1WmlEPTB;MD61O\|U6PSEQvF2=	M3zreHNCVkeHUh?=
MDA-MB-175-VII	MkLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13QWWlEPTB;MD61O\|c1OSEQvF2=	NF:1OmtUSU6JRWK=
MSTO-211H	NWrYdW5qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWS2OWk1UUN3ME2wMlU4PzVzIN88US=>	MlT6V2FPT0WU
ML-2	M1fnVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTBwNUi0O\|gh\|ryP	MojOV2FPT0WU
SCC-4	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHL4[I1KSzVyPUCuOVg2PDFizszN	NInING5USU6JRWK=
NCI-H1048	NHHFRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHVTWM2OD1yLkW4OlQ2KM7:TR?=	M{PsVHNCVkeHUh?=
NCI-H28	NH\DblFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfMTWM2OD1yLkW4Olc2KM7:TR?=	NFjZbY1USU6JRWK=
BCPAP	NWS4[mluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnMR21KSzVyPUCuOVg4QTFizszN	MofZV2FPT0WU
PC-14	MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU[weFI4UUN3ME2wMlU5QTdizszN	NH3HbZpUSU6JRWK=
OAW-42	M3\me2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXm3TVVCUUN3ME2wMlU6OTZ{IN88US=>	M3T3NXNCVkeHUh?=
IA-LM	MmG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDaTWM2OD1yLkW5OlA6KM7:TR?=	NFfVdldUSU6JRWK=
Hs-578-T	NHXzeVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrSdFh6UUN3ME2wMlU6QDVzIN88US=>	MYjTRW5ITVJ?
H4	NF\ZWVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\qXlJmUUN3ME2wMlYxODl2IN88US=>	MmfWV2FPT0WU
HL-60	Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEizXGZKSzVyPUCuOlA{PTFizszN	MorGV2FPT0WU
NCI-H1437	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33w[mlEPTB;MD62NFYyQSEQvF2=	MoLwV2FPT0WU
KGN	NHS2To5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTBwNkGwOFkh\|ryP	NELTTGlUSU6JRWK=
NCI-H2452	NF71PJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLUTmRSUUN3ME2wMlYyQTF5IN88US=>	MonEV2FPT0WU
BFTC-905	NYfobVk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3XNbmlEPTB;MD62NlEzPiEQvF2=	NHTXdWpUSU6JRWK=
CAMA-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWGyZZVPUUN3ME2wMlYzOTV{IN88US=>	NGfp[mNUSU6JRWK=
SK-NEP-1	MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnmwTWM2OD1yLk[yOVAzKM7:TR?=	NELyVZFUSU6JRWK=
NCI-H522	M4\memdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXryWnZvUUN3ME2wMlYzQTl{IN88US=>	NEKz[HlUSU6JRWK=
SW1710	NEHydYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjRcZVKSzVyPUCuOlMyPjdizszN	M131e3NCVkeHUh?=
RVH-421	NGHabIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4i1TGlEPTB;MD62N\|Y{QSEQvF2=	NYK3eHpZW0GQR1XS
SK-MEL-2	NEDNO4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLWVm0zUUN3ME2wMlY1OTV\|IN88US=>	MlSxV2FPT0WU
KYSE-150	MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTBwNk[xPFYh\|ryP	NFj6d4RUSU6JRWK=
MOLT-13	NFn1[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrFem5JUUN3ME2wMlY3PTN5IN88US=>	M2jXU3NCVkeHUh?=
SK-OV-3	NF\2doFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTBwNkexPFch\|ryP	NFKzfXpUSU6JRWK=
IGROV-1	MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTBwNke0OUDPxE1?	Mn2xV2FPT0WU
MOLT-4	MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHW0RZNKSzVyPUCuOlc3QDlizszN	MofmV2FPT0WU
MEL-HO	NGHtVXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HTe2lEPTB;MD62O\|c2OiEQvF2=	M{X5SXNCVkeHUh?=
MDA-MB-157	M1i0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjvbFJKSzVyPUCuOlc5OSEQvF2=	NFrnTopUSU6JRWK=
MN-60	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTBwNke4OFYh\|ryP	MoTEV2FPT0WU
EFO-27	NH31SmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{f3WmlEPTB;MD62O\|k4QSEQvF2=	MXfTRW5ITVJ?
HO-1-N-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEG1NZFKSzVyPUCuOlgxPjRizszN	MUjTRW5ITVJ?
TE-5	NGjiRplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LKR2lEPTB;MD62PFQxPSEQvF2=	NXTOZoJrW0GQR1XS
EW-22	NVHUPIhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NImxbHJKSzVyPUCuOlg1PDRizszN	MXjTRW5ITVJ?
SW982	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4exSWlEPTB;MD62PFUxOSEQvF2=	MlfiV2FPT0WU
SF295	NVTnbmFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13KUWlEPTB;MD62PFUxPyEQvF2=	NF;hW3ZUSU6JRWK=
WM-115	M37Mfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWjIWWp2UUN3ME2wMlY5QTJ2IN88US=>	NHjicWFUSU6JRWK=
COLO-800	M3PjVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXzUbZVHUUN3ME2wMlY6QDF\|IN88US=>	M1:xSHNCVkeHUh?=
NTERA-S-cl-D1	M4Tnfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn35TWM2OD1yLkewNFY{KM7:TR?=	NGPRV3RUSU6JRWK=
NCI-H1648	NWHKd\|B[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfaZW1KSzVyPUCuO\|AyPzNizszN	NWXYOVFtW0GQR1XS
NB5	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jTPGlEPTB;MD63NFMyQSEQvF2=	M1rZV3NCVkeHUh?=
ATN-1	M4DlV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmDuTWM2OD1yLkewOVkh\|ryP	NXXCPWk4W0GQR1XS
NUGC-3	NYPyV206T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIG2TG9KSzVyPUCuO\|A3QTFizszN	Mn;rV2FPT0WU
22RV1	NXnZPIxnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHkR\|JIUUN3ME2wMlcxPzF5IN88US=>	NInzV2FUSU6JRWK=
8305C	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF60OVNKSzVyPUCuO\|A4PTVizszN	NHTEUm1USU6JRWK=
EFM-19	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1L0ZWlEPTB;MD63NFg1PyEQvF2=	NGrSdY9USU6JRWK=
PC-3	NYnJc5FMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoW4TWM2OD1yLkeyNlMh\|ryP	NWjhUphkW0GQR1XS
C32	M2n3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTBwN{K0PFQh\|ryP	MW\TRW5ITVJ?
MC-IXC	M3v4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnXbXd4UUN3ME2wMlczPzF6IN88US=>	NIHUVFNUSU6JRWK=
OMC-1	MmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2DaOGlEPTB;MD63Nlc{QCEQvF2=	NH7v[45USU6JRWK=
HTC-C3	M{\sdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XrTmlEPTB;MD63N\|E4OiEQvF2=	NVm2N5BXW0GQR1XS
RPMI-7951	MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfBSlRKSzVyPUCuO\|M2OzNizszN	M{LYZXNCVkeHUh?=
AsPC-1	NYfofXFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHUTWM2OD1yLkezO\|k2KM7:TR?=	MmG0V2FPT0WU
CAKI-1	MmfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrjS5ZKSzVyPUCuO\|Q3OjlizszN	NIj1cW9USU6JRWK=
MHH-PREB-1	MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rFe2lEPTB;MD63OFc{PiEQvF2=	NF2zXFBUSU6JRWK=
HLE	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULxeYg3UUN3ME2wMlc1QDR2IN88US=>	MYXTRW5ITVJ?
A375	M1\sdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTBwN{WxPVMh\|ryP	NXvNTXJRW0GQR1XS
RS4-11	NUnPcWtGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGnBW49KSzVyPUCuO\|U6PDNizszN	MVfTRW5ITVJ?
U-2-OS	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2rSU2lEPTB;MD63OVk4KM7:TR?=	MlLEV2FPT0WU
NCI-H747	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTBwN{W5PVEh\|ryP	MlmzV2FPT0WU
NCI-H1623	NFnVXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTBwN{[yOlEh\|ryP	MVjTRW5ITVJ?
DMS-273	MlHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTBwN{[5NlIh\|ryP	NXrZSYxqW0GQR1XS
PSN1	M{P2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnK3TWM2OD1yLke3NFU4KM7:TR?=	MmjnV2FPT0WU
LU-99A	Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXhblNOUUN3ME2wMlc4PjR7IN88US=>	MlHkV2FPT0WU
CAL-12T	MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn62TWM2OD1yLke4NFI6KM7:TR?=	M1vXXnNCVkeHUh?=
KYSE-140	NV7EW\|lFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTBwN{ixOlgh\|ryP	NHe2O49USU6JRWK=
VMRC-RCZ	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHUTWM2OD1yLke4OFgzKM7:TR?=	MXPTRW5ITVJ?
Ca9-22	MljZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTBwN{i3N\|Yh\|ryP	Mke0V2FPT0WU
NCI-H1563	NXjreYo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIGzdldKSzVyPUCuO\|g6OjZizszN	NH3SN3pUSU6JRWK=
NCI-H650	Ml\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETXXo5KSzVyPUCuO\|kyPDRizszN	NVz2bmZWW0GQR1XS
DOHH-2	M2TNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTBwN{mzN{DPxE1?	MXvTRW5ITVJ?
OE33	Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoT6TWM2OD1yLke5PVE1KM7:TR?=	M1v5dHNCVkeHUh?=
CAL-62	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjrTXJKSzVyPUCuO\|k6OjRizszN	MXzTRW5ITVJ?
NCI-H1770	NInDblJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3y[WRKSzVyPUCuPFAzOSEQvF2=	M4q2XnNCVkeHUh?=
SN12C	MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHPTWM2OD1yLkiwOlY5KM7:TR?=	MoHWV2FPT0WU
HPAF-II	M{Huc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3r5VWlEPTB;MD64NFc6PCEQvF2=	M3jNcnNCVkeHUh?=
SNU-423	NIDMem5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmTzTWM2OD1yLkixOFIzKM7:TR?=	Mn7zV2FPT0WU
A704	NH21UZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHjTWM2OD1yLkixO\|k5KM7:TR?=	M4DScHNCVkeHUh?=
OVCAR-4	M3:yU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\XcWlEPTB;MD64NVkyOSEQvF2=	MmLKV2FPT0WU
NCI-H2347	NX2xelZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTBwOEK0NFEh\|ryP	MXvTRW5ITVJ?
OCUB-M	Ml\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXtbJlKSzVyPUCuPFI3PzVizszN	MWPTRW5ITVJ?
KYSE-450	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG[5SZZKSzVyPUCuPFI4OjVizszN	MoLwV2FPT0WU
PFSK-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXheYpMUUN3ME2wMlg{ODN7IN88US=>	M4PsbXNCVkeHUh?=
A431	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmC4TWM2OD1yLkizNVE3KM7:TR?=	NXjNXpZJW0GQR1XS
MHH-ES-1	NHn0OnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXaTWM2OD1yLkizOFU4KM7:TR?=	NEKxXFlUSU6JRWK=
HD-MY-Z	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGT4bpJKSzVyPUCuPFQxQTJizszN	MX7TRW5ITVJ?
RT-112	NIXmSHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTBwOES5N\|ch\|ryP	M3Tye3NCVkeHUh?=
KU-19-19	M4O3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\BPYtKSzVyPUCuPFUyOjFizszN	NFHmflNUSU6JRWK=
HCC1569	NFradpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3f5[mlEPTB;MD64OVIxPyEQvF2=	MnHjV2FPT0WU
RPMI-8866	NV:yNI9bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXvVoFKSzVyPUCuPFU5OjJizszN	MojZV2FPT0WU
CAL-120	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHiU5hnUUN3ME2wMlg3ODRzIN88US=>	NF3mfm9USU6JRWK=
CAL-33	M3SzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTBwOE[0PVUh\|ryP	M1ezO3NCVkeHUh?=
RKO	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPY[HJKSzVyPUCuPFY5OTdizszN	Mn3SV2FPT0WU
HCC1419	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4f4fWlEPTB;MD64OlkzQCEQvF2=	MmL2V2FPT0WU
CP50-MEL-B	MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jEdmlEPTB;MD64PFM5PCEQvF2=	MnjOV2FPT0WU
BPH-1	Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorJTWM2OD1yLki4N\|k2KM7:TR?=	M3LXbHNCVkeHUh?=
SF126	Mn\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXr2cplnUUN3ME2wMlg5PzF2IN88US=>	NYnRWHNEW0GQR1XS
BHY	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3J[lhxUUN3ME2wMlg5PzN2IN88US=>	NInaSJhUSU6JRWK=
BxPC-3	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTBwOEi4N\|Mh\|ryP	NX7uWm1UW0GQR1XS
ETK-1	M{LHZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13YbWlEPTB;MD64PVM4OiEQvF2=	M3;GcHNCVkeHUh?=
NCI-H1573	Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1ryWmlEPTB;MD65NFIzQSEQvF2=	MWfTRW5ITVJ?
C-33-A	M3f0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTBwOUC0OFIh\|ryP	M1Hq[3NCVkeHUh?=
UACC-893	NH;HZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LQO2lEPTB;MD65Nlg2PSEQvF2=	NIe4T25USU6JRWK=
RXF393	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnFeoZFUUN3ME2wMlkzQDl5IN88US=>	NUjTcXZQW0GQR1XS
MIA-PaCa-2	MnLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPtTnlHUUN3ME2wMlkzQTJ{IN88US=>	NYL4bZR1W0GQR1XS
HCC1806	Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfJTWM2OD1yLkmzNlU3KM7:TR?=	MVPTRW5ITVJ?
DMS-114	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUn2dGc1UUN3ME2wMlk{Pjd5IN88US=>	NWPsUYtkW0GQR1XS
MOLT-16	NULRcZRIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTBwOUO4OFUh\|ryP	MUPTRW5ITVJ?
ACN	M2jVfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NInoNlFKSzVyPUCuPVQzPzdizszN	NH73T\|JUSU6JRWK=
SNU-449	NIjRSYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjEToRTUUN3ME2wMlk2QTJ2IN88US=>	MWfTRW5ITVJ?
A427	NYXFRop7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4ixfmlEPTB;MD65OlE6QCEQvF2=	M16xZ3NCVkeHUh?=
DEL	NWPXdGFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;ONYJKSzVyPUCuPVY4PzNizszN	NHLZUodUSU6JRWK=
NCI-H1792	M{DhZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvGTWM2OD1yLkm3NVAyKM7:TR?=	NED0OJVUSU6JRWK=
A2058	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\GepQ6UUN3ME2wMlk4OzZizszN	M3m5WnNCVkeHUh?=
SW13	M2K3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTBwOUizPVIh\|ryP	M37GUnNCVkeHUh?=
T98G	M2XnTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PDZ2lEPTB;MT6wNVM3PCEQvF2=	M2D3OHNCVkeHUh?=
LU-134-A	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnITWM2OD1zLkCyOlc2KM7:TR?=	MULTRW5ITVJ?
GI-ME-N	NGHjNlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHXd2xKSzVyPUGuNFI5OjdizszN	M4Ts[XNCVkeHUh?=
D-423MG	NXO3[I5JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWS5WXQ5UUN3ME2xMlAzQTZ\|IN88US=>	MonMV2FPT0WU
PANC-03-27	NILq[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTFwMEOxOFEh\|ryP	MmrrV2FPT0WU
P12-ICHIKAWA	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXBdGZMUUN3ME2xMlA{PDB4IN88US=>	NE[zR\|BUSU6JRWK=
SCH	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLvTWM2OD1zLkCzOFUh\|ryP	NF;Vdm9USU6JRWK=
D-566MG	M1\VPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1G3RWlEPTB;MT6wOlczPiEQvF2=	NVfDTWN5W0GQR1XS
OS-RC-2	M3Llb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTFwMEe5OEDPxE1?	MWXTRW5ITVJ?
KOSC-2	MmTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDSXpNiUUN3ME2xMlA5ODJzIN88US=>	MVXTRW5ITVJ?
SH-4	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTFwMEi0N\|Eh\|ryP	NFLFcnJUSU6JRWK=
786-0	MoPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1ToVWlEPTB;MT6wPFk{PCEQvF2=	NXi1U3UyW0GQR1XS
Mewo	Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHCZ4tUUUN3ME2xMlA6OjR6IN88US=>	NIrv[HFUSU6JRWK=
AGS	NEn0VpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTFwMEm0OVkh\|ryP	NF\FRoFUSU6JRWK=
Daoy	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Moj5TWM2OD1zLkC5OlI5KM7:TR?=	NIPkR2xUSU6JRWK=
SW48	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1WyVGlEPTB;MT6xNFkyOSEQvF2=	MVnTRW5ITVJ?
KYSE-180	NV75UnliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\WTWM2OD1zLkGxNFIyKM7:TR?=	NYLQblRNW0GQR1XS
NH-12	M33ib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXnjRmFUUUN3ME2xMlEyOjN5IN88US=>	Mn;HV2FPT0WU
BE-13	NVXJNIRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUm2XmZiUUN3ME2xMlEyPzV7IN88US=>	Mo\BV2FPT0WU
ES3	MnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LUW2lEPTB;MT6xN\|E4OSEQvF2=	NWjDcXdQW0GQR1XS
NCI-H1092	MlzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlTyTWM2OD1zLkGzOEDPxE1?	M4HGSHNCVkeHUh?=
NCI-H1755	M4\UVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXPMUWdOUUN3ME2xMlE{QTRzIN88US=>	Mm\mV2FPT0WU
EKVX	NGixVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLBT4Z1UUN3ME2xMlE1ODBzIN88US=>	MoHnV2FPT0WU
NB13	M1zQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmr5TWM2OD1zLkG0OFUh\|ryP	M3vKZnNCVkeHUh?=
NCI-H2405	NXHMS5NsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfjXHhKSzVyPUGuNVQ2PzRizszN	M{O5fXNCVkeHUh?=
LS-411N	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHntNY1KSzVyPUGuNVUxOTdizszN	MYDTRW5ITVJ?
MDA-MB-453	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnBU2dVUUN3ME2xMlE2PjJ2IN88US=>	NX[4dm9WW0GQR1XS
SCC-15	NF7zWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTFwMU[5OVYh\|ryP	NYH0[mZtW0GQR1XS
C2BBe1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnwTWM2OD1zLkG3NFU3KM7:TR?=	MXfTRW5ITVJ?
HT-144	MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnaWJdvUUN3ME2xMlE4ODdizszN	NVTWdYVZW0GQR1XS
HEC-1	Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\OfnBKSzVyPUGuNVc3OjdizszN	MlLFV2FPT0WU
HCE-T	NELYPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWL4Z\|Z5UUN3ME2xMlE4QTh\|IN88US=>	MVrTRW5ITVJ?
IST-MEL1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPNUoJKSzVyPUGuNVkxQDJizszN	NVrxN5ViW0GQR1XS
Detroit562	M4\PVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTFwMUm0N\|kh\|ryP	NFLGOoZUSU6JRWK=
A4-Fuk	M1PTUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvNTWM2OD1zLkKwOFQyKM7:TR?=	MYfTRW5ITVJ?
HDLM-2	NYDMOGx{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MonJTWM2OD1zLkKxN\|I3KM7:TR?=	NYi0bZBFW0GQR1XS
MKN7	NEHjSJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zvWGlEPTB;MT6yNVcxOiEQvF2=	NWLy[4ZGW0GQR1XS
MDA-MB-415	NXfuRZNCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXJdYxKSzVyPUGuNlE4ODJizszN	M{DidnNCVkeHUh?=
BT-20	NEPBZ29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jtTmlEPTB;MT6yNlQ1PCEQvF2=	NXLzVm9RW0GQR1XS
NCI-H2030	M3HkUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIf6dWxKSzVyPUGuNlQyODZizszN	M{W2[XNCVkeHUh?=
LS-123	M2\td2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml34TWM2OD1zLkK0O\|U{KM7:TR?=	NVTURY9HW0GQR1XS
SK-MEL-3	NYjpeIttT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\KTWM2OD1zLkK0O\|c3KM7:TR?=	NUDOdHFQW0GQR1XS
KS-1	NX3jZms5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTFwMkWxO\|Eh\|ryP	MXXTRW5ITVJ?
LU-65	NHzQ[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXSwOJY2UUN3ME2xMlI2PjB4IN88US=>	MmDCV2FPT0WU
NCI-H596	MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTFwMkW5Nlkh\|ryP	NFzVS5BUSU6JRWK=
KYSE-410	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3v4[WlEPTB;MT6yO\|AyPCEQvF2=	MVvTRW5ITVJ?
NCI-H2228	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjOWldKSzVyPUGuNlcyPjdizszN	MYrTRW5ITVJ?
LN-405	NEOzRoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnf3TWM2OD1zLkK4NFIyKM7:TR?=	NYXTd2pwW0GQR1XS
8505C	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTpTWM2OD1zLkK4PFI{KM7:TR?=	M164bnNCVkeHUh?=
BFTC-909	NF;LZ2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn3OTWM2OD1zLkK5OFM1KM7:TR?=	NGnMXlVUSU6JRWK=
OC-314	NXfzU2VFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jIXWlEPTB;MT6yPVkzQSEQvF2=	NVTwNVdkW0GQR1XS
NMC-G1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDwSmdyUUN3ME2xMlMyOTN3IN88US=>	MXvTRW5ITVJ?
SKG-IIIa	NETONGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlv1TWM2OD1zLkOxOFI5KM7:TR?=	NIXFUmhUSU6JRWK=
GAK	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTFwM{G4OVgh\|ryP	MXTTRW5ITVJ?
D-263MG	NVfSdZdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEi2V5BKSzVyPUGuN\|I3PDFizszN	MkXYV2FPT0WU
NCI-H446	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTFwM{K5NFIh\|ryP	NVu3RZJlW0GQR1XS
TGBC1TKB	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjTc41KSzVyPUGuN\|I6QThizszN	NF22dGFUSU6JRWK=
GCT	NIfLfWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzYdFRKSzVyPUGuN\|Q{PDVizszN	MY\TRW5ITVJ?
COR-L23	MlnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTFwM{S4OFUh\|ryP	MX3TRW5ITVJ?
TK10	Mn;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFu1[4RKSzVyPUGuN\|U4QTdizszN	MlfTV2FPT0WU
ES6	NFy2fnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXsfXRKSzVyPUGuN\|Y{PzZizszN	MVTTRW5ITVJ?
SW1088	MnTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWe1XpVCUUN3ME2xMlM3PjF{IN88US=>	NUn2[mFlW0GQR1XS
AM-38	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrnTWM2OD1zLkO3NVk6KM7:TR?=	NGW1SZJUSU6JRWK=
CHP-134	M1zu[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFe1XZdKSzVyPUGuN\|c5PDRizszN	NGHqSGlUSU6JRWK=
SW872	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1L4R2lEPTB;MT6zPFU2PSEQvF2=	MXrTRW5ITVJ?
LB831-BLC	MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;adYM2UUN3ME2xMlM6ODZ5IN88US=>	NYDkTo9KW0GQR1XS
TE-12	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LpbGlEPTB;MT60NFYxOSEQvF2=	MmHSV2FPT0WU
LCLC-97TM1	NUH6[ZFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHkfGVKSzVyPUGuOFExPDZizszN	MnnZV2FPT0WU
HCT-116	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvTN3RKSzVyPUGuOFI5PTRizszN	MUjTRW5ITVJ?
ALL-PO	MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWSydphHUUN3ME2xMlQ{Pzd2IN88US=>	Ml3zV2FPT0WU
EW-16	MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnT4TWM2OD1zLkSzPFQzKM7:TR?=	M2W4RXNCVkeHUh?=
NCI-H661	MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTFwNES3O\|Uh\|ryP	MXvTRW5ITVJ?
TE-8	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2rSTWlEPTB;MT60OVU3KM7:TR?=	NYTjV4dvW0GQR1XS
TCCSUP	NI\QRoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTFwNE[5OkDPxE1?	NWe0ZmdqW0GQR1XS
SW1990	M{j3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml61TWM2OD1zLkS3OVM{KM7:TR?=	NYKxR3V4W0GQR1XS
UM-UC-3	NXPre4U1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn61TWM2OD1zLkS3Olc2KM7:TR?=	M3rqPHNCVkeHUh?=
HuP-T4	M4LVR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTFwNEi2NFch\|ryP	NEnNSJRUSU6JRWK=
NCI-H1299	NFPLTZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTFwNUCwPFYh\|ryP	NHHnZ2NUSU6JRWK=
RO82-W-1	MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXVcJVrUUN3ME2xMlUzODhzIN88US=>	MWPTRW5ITVJ?
Becker	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVq4S\|VoUUN3ME2xMlUzOTh5IN88US=>	MXHTRW5ITVJ?
SNU-387	MkTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTFwNUKyOFEh\|ryP	M2Xq[3NCVkeHUh?=
CAL-85-1	NGj4c\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTFwNUK1PVkh\|ryP	NWm2OoF4W0GQR1XS
647-V	NXPtR4tuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlflTWM2OD1zLkWzPFgh\|ryP	MXXTRW5ITVJ?
SBC-5	NUL0UGVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXQTWM2OD1zLkW0OVk{KM7:TR?=	M4qyfnNCVkeHUh?=
NCI-H23	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn2wTWM2OD1zLkW1O\|E1KM7:TR?=	MkH1V2FPT0WU
CGTH-W-1	NGj6[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofnTWM2OD1zLkW1PFE6KM7:TR?=	M1q5dHNCVkeHUh?=
SK-N-FI	NGS4XZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{nHOWlEPTB;MT61OVkxQCEQvF2=	NI\ENVRUSU6JRWK=
KM-H2	MlixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDyWJlKSzVyPUGuOVY1PzRizszN	MofqV2FPT0WU
KY821	NWXQZVVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3rSe2lEPTB;MT61OlYyPyEQvF2=	NHr2RVNUSU6JRWK=
RH-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LzWWlEPTB;MT61Olc3OiEQvF2=	NGLifGVUSU6JRWK=
KYSE-270	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1v0[WlEPTB;MT61O\|QzOyEQvF2=	MYHTRW5ITVJ?
SF539	NFHQO2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPRWphLUUN3ME2xMlU4QTZ7IN88US=>	NFPyenpUSU6JRWK=
JEG-3	NH;vc3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPWTWM2OD1zLkW4NFk1KM7:TR?=	MleyV2FPT0WU
SCC-25	M1\Wemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTFwNUi0N\|Ih\|ryP	NYLaPJMxW0GQR1XS
SW1573	Mlf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDXdYFKUUN3ME2xMlYxOTV6IN88US=>	MYPTRW5ITVJ?
EW-1	NHeweYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXSW2ZJUUN3ME2xMlYyOzVzIN88US=>	MVLTRW5ITVJ?
YKG-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXOUFN5UUN3ME2xMlYyPDN6IN88US=>	M{DRUXNCVkeHUh?=
EW-11	M3jJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;LN5lPUUN3ME2xMlYyPzRzIN88US=>	NIfPSIJUSU6JRWK=
DJM-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTFwNkG4NlUh\|ryP	Mnm2V2FPT0WU
Calu-3	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTFwNkWyNVMh\|ryP	Mo\KV2FPT0WU
HT-3	NET5RnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\0UGlEPTB;MT62OVY3KM7:TR?=	NVq3d45KW0GQR1XS
NCI-H69	NWPBNlBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTFwNkezOFMh\|ryP	NULVOJJlW0GQR1XS
NCI-H2126	M1z4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvQcYFyUUN3ME2xMlY4Pzl5IN88US=>	M{n0eXNCVkeHUh?=
RPMI-2650	M1vHNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zSSmlEPTB;MT62PFMyPyEQvF2=	M1TE[3NCVkeHUh?=
TE-6	NUTLTotZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPlPXRKSzVyPUGuO\|A5PzRizszN	NFmyWWtUSU6JRWK=
MDA-MB-231	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHUTWM2OD1zLkexPVk{KM7:TR?=	Mn\JV2FPT0WU
A2780	MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEHY[ZdKSzVyPUGuO\|IzODdizszN	NF;zWo9USU6JRWK=
GOTO	NUX2SYlpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLhXIU2UUN3ME2xMlc{PTZizszN	MlywV2FPT0WU
KYSE-70	NGDOVpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXvNIJKSzVyPUGuO\|Q1PDJizszN	NFraZYFUSU6JRWK=
GMS-10	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTFwN{S2OlIh\|ryP	M{LQN3NCVkeHUh?=
CaR-1	Mlf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrtepZKSzVyPUGuO\|Q5OTJizszN	NWfJTmc4W0GQR1XS
SW900	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1[xUWlEPTB;MT63OFk6OyEQvF2=	NWDIbVZEW0GQR1XS
BB49-HNC	NVfDemRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3Xk[WlEPTB;MT63OVE3QCEQvF2=	NXTSfVU5W0GQR1XS
SNB75	M4rEO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3VTWM2OD1zLke1OFkzKM7:TR?=	MWTTRW5ITVJ?
SK-PN-DW	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTFwN{W2PFIh\|ryP	NEDjNI5USU6JRWK=
5637	NHHhXlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnsTWM2OD1zLke3NlY5KM7:TR?=	M{LqVnNCVkeHUh?=
BT-474	NY\BZZN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzIbWFKSzVyPUGuO\|gyPzFizszN	MkiwV2FPT0WU
KM12	NFG4dIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjGfolKSzVyPUGuO\|k4PDFizszN	NGHROmxUSU6JRWK=
COLO-680N	NEjvVZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2KyO2lEPTB;MT64NlM5OSEQvF2=	M{jWWHNCVkeHUh?=
Saos-2	NFLScItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3nBNWlEPTB;MT64NlQ1PSEQvF2=	NV76d41oW0GQR1XS
CAL-54	M1T5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;qTWM2OD1zLkizN\|E{KM7:TR?=	MWTTRW5ITVJ?
U-118-MG	M1Xl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjCZnBKSzVyPUGuPFQ3OjJizszN	MYHTRW5ITVJ?
TGBC24TKB	M2\TVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTFwOEW1NFEh\|ryP	M2OybnNCVkeHUh?=
NCI-H2052	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfCXmhKSzVyPUGuPFY1OSEQvF2=	NWCw[ItGW0GQR1XS
BB30-HNC	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NETy[FdKSzVyPUGuPFY1PjJizszN	NX2yZ\|R{W0GQR1XS
KNS-81-FD	M3H4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LYcWlEPTB;MT64PVE3PSEQvF2=	NFTDbXJUSU6JRWK=
HN	NFTUXmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTFwOEm1OFUh\|ryP	NHXxR5pUSU6JRWK=
ACHN	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV[5TWl[UUN3ME2xMlkxPzh4IN88US=>	MWjTRW5ITVJ?
HSC-2	MojxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2SzW2lEPTB;MT65NVA6PiEQvF2=	M{TXTXNCVkeHUh?=
HCC2998	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHHS[VRKSzVyPUGuPVM{OjVizszN	MoXSV2FPT0WU
HEL	M1\wOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{i3[GlEPTB;MT65OFE5PCEQvF2=	M{HGSHNCVkeHUh?=
SW684	M{L6Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTFwOUezO\|Eh\|ryP	MXzTRW5ITVJ?
NCI-H1693	NXvWN24xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHG0fW9KSzVyPUGuPVgxQDZizszN	NUDvWIt2W0GQR1XS
8-MG-BA	NGDLb4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33S[mlEPTB;MT65PFIyKM7:TR?=	M2HKdHNCVkeHUh?=
OVCAR-8	NYTGVoVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7BTVNvUUN3ME2yMlAxOjl3IN88US=>	MkLPV2FPT0WU
DSH1	MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LGUWlEPTB;Mj6wNVc4PCEQvF2=	MmH1V2FPT0WU
KYSE-520	NX7YeI1LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlz3TWM2OD1{LkCyNFQ6KM7:TR?=	MU\TRW5ITVJ?
GB-1	MkfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3uxZ2lEPTB;Mj6wNlU4PyEQvF2=	NVrDZ29yW0GQR1XS
RCC10RGB	MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zSPWlEPTB;Mj6wOFg4OSEQvF2=	NH33PGdUSU6JRWK=
SW954	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLNTWM2OD1{LkC1NFM3KM7:TR?=	MX;TRW5ITVJ?
IST-MES1	NYjxNodZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTJwMEW1Olgh\|ryP	MV\TRW5ITVJ?
AU565	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HrWmlEPTB;Mj6wOVkxPSEQvF2=	MW\TRW5ITVJ?
CW-2	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITtfI1KSzVyPUKuNFY5PzVizszN	M3Kxe3NCVkeHUh?=
TE-1	NGDQ[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjC[nVKSzVyPUKuNFk{PzdizszN	M3LNPHNCVkeHUh?=
KP-4	M{DOUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXlTWM2OD1{LkGwN\|EzKM7:TR?=	NH\SeG9USU6JRWK=
SNU-C2B	M1H3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{K2NGlEPTB;Mj6xNFgzOyEQvF2=	NG\h[mdUSU6JRWK=
NCI-H1395	Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{nOSmlEPTB;Mj6xNFk5PiEQvF2=	NYDmRoZwW0GQR1XS
CAS-1	NVnOSohPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDxTWM2OD1{LkGxOVQ3KM7:TR?=	MkfoV2FPT0WU
NCI-H1155	NGjpO\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3ySYZKSzVyPUKuNlI3QSEQvF2=	NE\OZ\|hUSU6JRWK=
SK-MEL-1	M3HJXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3WwZ2lEPTB;Mj6yPFE5OSEQvF2=	M4HiZXNCVkeHUh?=
KINGS-1	M1PPcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXzrTXNxUUN3ME2yMlMxODh6IN88US=>	NEfM[4xUSU6JRWK=
ESS-1	MkTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn6zTWM2OD1{LkOwOVEh\|ryP	NGLUenhUSU6JRWK=
PANC-10-05	NWq0[YxHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGT2WJJKSzVyPUKuN\|cxOjRizszN	NFjO[WFUSU6JRWK=
HT-1376	M3[yZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTJwM{i3NFgh\|ryP	Mlj2V2FPT0WU
LS-513	NEPiW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU[2PJNMUUN3ME2yMlM5QDd2IN88US=>	M3;SbXNCVkeHUh?=
KNS-42	NULBXlRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXkTJJKSzVyPUKuN\|kyODVizszN	NIjtXXdUSU6JRWK=
639-V	NWDVe4dFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTJwNEK3OVgh\|ryP	NF;xS3NUSU6JRWK=
SJRH30	NGTSTYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTJwNEWxOlEh\|ryP	Mo\RV2FPT0WU
SW1783	NY\W[ZN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXmzNYZtUUN3ME2yMlQ4ODd6IN88US=>	M2LRc3NCVkeHUh?=
NB6	NIHIeoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7j[\|JYUUN3ME2yMlQ5OjhizszN	NXOyOHg3W0GQR1XS
SK-MEL-30	NVTCNpY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4TndGlEPTB;Mj60PFg{KM7:TR?=	NXrreYh5W0GQR1XS
HCE-4	NUPhcmhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDuTWM2OD1{LkS5OFAzKM7:TR?=	M4\FfHNCVkeHUh?=
NB10	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTJwNEm0Nlkh\|ryP	MUfTRW5ITVJ?
H-EMC-SS	NWC4eYVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXnTWM2OD1{LkW0OlUh\|ryP	NGftdItUSU6JRWK=
SK-HEP-1	NVvWenlkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33YNmlEPTB;Mj61OVI{PiEQvF2=	NH3jUpZUSU6JRWK=
HCC1395	M1PGO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjlTllKSzVyPUKuOVU3PTVizszN	NHrpTJFUSU6JRWK=
HuCCT1	M4jrOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfZ[XNKSzVyPUKuOVY{QSEQvF2=	MnHnV2FPT0WU
SiHa	NXriUYN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\mS\|FKSzVyPUKuOVg4OTlizszN	NEjvSY1USU6JRWK=
EFO-21	NHHGNpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrMTWM2OD1{LkW4O\|Y1KM7:TR?=	NF7qbZdUSU6JRWK=
NCI-H1666	MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jiPWlEPTB;Mj61PVA4PiEQvF2=	MkHoV2FPT0WU
UMC-11	Mlr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXr0WWl6UUN3ME2yMlU6QDZ6IN88US=>	MV\TRW5ITVJ?
COLO-679	NILxRY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XKcWlEPTB;Mj62NVI{OyEQvF2=	MnzUV2FPT0WU
A388	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTTTWM2OD1{Lk[1NlU{KM7:TR?=	NWTyT49vW0GQR1XS
LB2518-MEL	NFfIVllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXuRmVKSzVyPUKuOlU1ODhizszN	M2CyXHNCVkeHUh?=
EW-13	M334RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTJwNki3Olgh\|ryP	NULWPJE1W0GQR1XS
MLMA	NH3STmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\PTWM2OD1{Lk[4PFU3KM7:TR?=	NFXiWnhUSU6JRWK=
HOP-92	MljHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\ORWVKSzVyPUKuO\|AyOSEQvF2=	NYfK[WV{W0GQR1XS
NOMO-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLDfZhKSzVyPUKuO\|E1PDJizszN	M4fzeXNCVkeHUh?=
NCI-H810	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PxRWlEPTB;Mj63NlE6QCEQvF2=	NIDx[WRUSU6JRWK=
769-P	NYO0cXUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTJwN{KyPEDPxE1?	Mn7BV2FPT0WU
SAS	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnZTVg1UUN3ME2yMlc3PSEQvF2=	NGDHZnBUSU6JRWK=
M059J	NEjLeoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmeyTWM2OD1{Lke4N\|E5KM7:TR?=	NILjeFhUSU6JRWK=
RD	NIPjSGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTITWM2OD1{Lke5OFcyKM7:TR?=	M{LhVnNCVkeHUh?=
GT3TKB	M1rzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzWTWM2OD1{LkizOFM{KM7:TR?=	NX7EV\|l[W0GQR1XS
MZ7-mel	NVzZTGhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkT1TWM2OD1{Lki2OVAzKM7:TR?=	MlT1V2FPT0WU
KYSE-510	NX35SYcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4S2fGlEPTB;Mj64PVUxPCEQvF2=	MVzTRW5ITVJ?
NCI-N87	NGjOd3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnjNYJKSzVyPUKuPVE5ODdizszN	NGS1bmFUSU6JRWK=
MKN1	NEXnT5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjGNGNKSzVyPUOuNFAyPjNizszN	NXLrSml2W0GQR1XS
NCI-H2170	Mke0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDJOllGUUN3ME2zMlAxPDVzIN88US=>	MnXpV2FPT0WU
OVCAR-3	NFrQcGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmX0TWM2OD1\|LkCyNVE2KM7:TR?=	MWnTRW5ITVJ?
KLE	NHrPRoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXCblJKSzVyPUOuNFY5OTJizszN	M1X2fHNCVkeHUh?=
LB771-HNC	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEe0No1KSzVyPUOuNFk{PDNizszN	M1u2THNCVkeHUh?=
MC116	M4XORmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{m3fGlEPTB;Mz6xNVEyOiEQvF2=	MY\TRW5ITVJ?
SCC-9	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37zWGlEPTB;Mz6xNVM3PiEQvF2=	MVTTRW5ITVJ?
U031	NX3VTXNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;4dmlEPTB;Mz6xNlQzOyEQvF2=	M4Lwb3NCVkeHUh?=
LCLC-103H	NY\INmJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3rQdWlEPTB;Mz6yN\|g6PCEQvF2=	NGfoOohUSU6JRWK=
U-266	MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTNwMke2N\|Mh\|ryP	NVzueWM2W0GQR1XS
JVM-2	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHwTWM2OD1\|LkOyNVY1KM7:TR?=	NHvWe4pUSU6JRWK=
UACC-257	NIrTZ21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoCyTWM2OD1\|LkS2OFMyKM7:TR?=	MWPTRW5ITVJ?
LB996-RCC	M2T4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTtbIVoUUN3ME2zMlQ3PTB{IN88US=>	MoLwV2FPT0WU
BT-549	MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrsNVRKSzVyPUOuOVAzODlizszN	MYDTRW5ITVJ?
NCI-H526	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHNbXRKSzVyPUOuOVQyPThizszN	MoW4V2FPT0WU
RH-18	NWC0XG11T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjCRoNKSzVyPUOuOlE4QThizszN	NYTsW2ZQW0GQR1XS
SW626	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jHPGlEPTB;Mz63NVEzQCEQvF2=	NVT0UnVZW0GQR1XS
SK-N-AS	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPCPW0yUUN3ME2zMlc{OjR5IN88US=>	NWi4Xo5FW0GQR1XS
IGR-1	NWj6NJkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTNwN{SyOFgh\|ryP	NFvmdGtUSU6JRWK=
NCI-H2291	NXrTXYZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfpSmxKSzVyPUOuO\|U{OzZizszN	MnnZV2FPT0WU
NCI-H441	MoLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmWxTWM2OD1\|LkiyOFM{KM7:TR?=	M{HGRnNCVkeHUh?=
D-247MG	NHLxbIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLMTWM2OD1\|Lki2NFMyKM7:TR?=	Mke0V2FPT0WU
COLO-320-HSR	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2nIeWlEPTB;Mz65NVI4OSEQvF2=	M1fodnNCVkeHUh?=
A253	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEDNOVhKSzVyPUOuPVE1OzZizszN	NGDFVpdUSU6JRWK=
HT55	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTNwOUG3O\|Mh\|ryP	NWnTb3p4W0GQR1XS
MZ1-PC	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTNwOUW4OlQh\|ryP	MknHV2FPT0WU
RERF-LC-MS	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\YbplpUUN3ME2zMlk3PTJ3IN88US=>	NWS4NItPW0GQR1XS
SF268	Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TzTGlEPTB;ND6xNlg5OSEQvF2=	M4\lXnNCVkeHUh?=
RMG-I	NED3[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTRwMkG0OVQh\|ryP	MXHTRW5ITVJ?
CFPAC-1	M4DvXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEDwVZRKSzVyPUSuNlE3QDVizszN	M{PJd3NCVkeHUh?=
S-117	NF21UlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHD[IRJUUN3ME20MlIzODJ2IN88US=>	MX\TRW5ITVJ?
NCI-H2122	MmXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTRwM{C5N\|Eh\|ryP	NIHMWWFUSU6JRWK=
J82	NUPzRpkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTRwM{O0OFEh\|ryP	MYDTRW5ITVJ?
CAL-72	MmnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLnTWM2OD12LkO1OFc4KM7:TR?=	MVHTRW5ITVJ?
GP5d	MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEPXWYxKSzVyPUSuOFEzQThizszN	NHrwT5FUSU6JRWK=
UACC-62	Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojJTWM2OD12LkS2OVQ2KM7:TR?=	NXy1bZNjW0GQR1XS
MS-1	NH3xb\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1j5SGlEPTB;ND60PVEyPSEQvF2=	MkfCV2FPT0WU
RCM-1	NVzoUo1WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTRwNUK5NkDPxE1?	M2\yfnNCVkeHUh?=
IST-SL1	NInNbXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PRU2lEPTB;ND62OVM2QSEQvF2=	MYTTRW5ITVJ?
SW756	NVLONXQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzY[2JKSzVyPUSuOlkyOzVizszN	MlK4V2FPT0WU
HCC38	NF\wenhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTRwN{GxPVch\|ryP	MX;TRW5ITVJ?
YAPC	M33OR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTRwN{GzNVMh\|ryP	NIPlWJNUSU6JRWK=
DK-MG	MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NInkVppKSzVyPUSuO\|gyOTJizszN	NXnHSHlmW0GQR1XS
HCC1937	NIi2NWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LmbWlEPTB;ND64OVEzPSEQvF2=	NEG3e5hUSU6JRWK=
OAW-28	NF33OGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknBTWM2OD12LkmyOFM2KM7:TR?=	MXnTRW5ITVJ?
MEG-01	NHfOcZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjXVnpKSzVyPUWuNFg{OjhizszN	M36ySXNCVkeHUh?=
GI-1	NEDJ[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV:2e3hWUUN3ME21MlI{PDh4IN88US=>	Mk\UV2FPT0WU
FADU	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mly3TWM2OD13LkK3PFM4KM7:TR?=	M3H5dHNCVkeHUh?=
CAPAN-1	MkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFvjTXdKSzVyPUWuN\|k1OzJizszN	NIrLU3BUSU6JRWK=
TGBC11TKB	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vyT2lEPTB;NT60OVc5PiEQvF2=	NGDhSphUSU6JRWK=
DBTRG-05MG	NYq3NJB6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTVwNUC1NkDPxE1?	M2ntdnNCVkeHUh?=
ONS-76	MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUKzeZdEUUN3ME21MlU2QDBzIN88US=>	MojDV2FPT0WU
Ca-Ski	NFjn[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF;pbHFKSzVyPUWuOlI2PjZizszN	MnHiV2FPT0WU
COLO-741	NILzSmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTVwN{G5PVUh\|ryP	NVjTOXpVW0GQR1XS
HT-29	NHfKZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\ySHdKSzVyPUWuPFA1PzVizszN	NH\0RodUSU6JRWK=
HCC1187	NE[wVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTVwOEGwNFgh\|ryP	NFjzXFRUSU6JRWK=
Capan-2	NXOzb2dWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFj4fnFKSzVyPUWuPVU6QTRizszN	MVPTRW5ITVJ?
NCI-H630	NFriU\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGm2b\|FKSzVyPU[uNVE1PDFizszN	MkXuV2FPT0WU
COLO-678	NH7y[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{n5bmlEPTB;Nj6xOVA6OiEQvF2=	Mnv6V2FPT0WU
D-502MG	NF\pOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\wTWM2OD14LkG3N\|M3KM7:TR?=	NH[3SY1USU6JRWK=
NB17	MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIjhSIFKSzVyPU[uNlQ6PDNizszN	MWjTRW5ITVJ?
SK-MEL-24	NEnsVpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPsOG9KSzVyPU[uNlY1QSEQvF2=	M1rRc3NCVkeHUh?=
NCI-SNU-5	MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGjKXWlKSzVyPU[uNlcyOThizszN	M3nuc3NCVkeHUh?=
D-392MG	NHm2[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnu[4tKSzVyPU[uN\|M{QTlizszN	NH;Sb25USU6JRWK=
A498	NW\hcVJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPsSZJKSzVyPU[uOFA{ODJizszN	MlPYV2FPT0WU
OCI-AML2	MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHkR49KSzVyPU[uOFU1PDVizszN	NXzSeoVRW0GQR1XS
HCC2157	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLaTWM2OD14LkS1OlE3KM7:TR?=	NUj6UHB2W0GQR1XS
C3A	M3OwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXCO\|dKSzVyPU[uOVIxODRizszN	M1TXdXNCVkeHUh?=
NCI-H1650	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXaU2hHUUN3ME22MlcxPTJ{IN88US=>	NXrDbFhkW0GQR1XS
DU-145	MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTZwN{ewN{DPxE1?	NYPKSJZHW0GQR1XS
COLO-829	M4PKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHETWM2OD14Lke3PFc{KM7:TR?=	M{n2OXNCVkeHUh?=
LS-1034	MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWG3XnlDUUN3ME23MlA1PDF{IN88US=>	MnzWV2FPT0WU
HCC1954	NF3acnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1K0dWlEPTB;Nz60PFE{PCEQvF2=	NVewSmM5W0GQR1XS
KURAMOCHI	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvBW3FKSzVyPUeuOFg2OzNizszN	NG\kXIxUSU6JRWK=
Mo-T	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\JTJJKSzVyPUeuOVE1QThizszN	NGm1ZVRUSU6JRWK=
OE19	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTlTWM2OD15Lk[1OVA{KM7:TR?=	Ml33V2FPT0WU
COR-L105	NEe5N3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4S1fmlEPTB;Nz63NVQzOSEQvF2=	NVPpWnFGW0GQR1XS
NCI-H2342	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTdwN{G1NlEh\|ryP	NHXUWnJUSU6JRWK=
U-87-MG	M{e1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NInXWoRKSzVyPUiuNFM{OzRizszN	NIDSd5VUSU6JRWK=
MKN28	NEfyPJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRThwMUG1NVUh\|ryP	MVnTRW5ITVJ?
HT-1197	NE[yZ2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRThwMkW5NFch\|ryP	MmDPV2FPT0WU
ChaGo-K-1	M1ew[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRThwM{SyOFUh\|ryP	MV\TRW5ITVJ?
NCI-H226	NHj5dHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;oZplyUUN3ME24MlQ1OzNzIN88US=>	NG\o[IlUSU6JRWK=
NCI-H2029	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILHcmVKSzVyPUmuNFY4PTlizszN	MlXpV2FPT0WU
TE-11	M{nFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3W0dGlEPTB;OT60OVU5QCEQvF2=	MYPTRW5ITVJ?
ZR-75-30	NWTkZZl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTFTWM2OD17LkmyOlM1KM7:TR?=	Ml7BV2FPT0WU
SW837	NXrnNIZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDpTWM2OD1zMD6yNlk{KM7:TR?=	MmDWV2FPT0WU
NCI-H1651	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYC5NHd4UUN3ME2xNE4zOzJ4IN88US=>	NFf4fIJUSU6JRWK=
NCI-H727	MlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\LVoU6UUN3ME2xNE41PDl3IN88US=>	M3\hOHNCVkeHUh?=
NCI-H358	M1uyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHX1ZY5KSzVyPUGwMlg{PjVizszN	NFHQ[2dUSU6JRWK=
NCI-H2087	MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\XTWM2OD1zMT6wOFM1KM7:TR?=	MYfTRW5ITVJ?
FTC-133	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3lUHFKSzVyPUGxMlQxPTFizszN	MYnTRW5ITVJ?
LAN-6	M3LG[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PQ[GlEPTB;MUKuNVI1KM7:TR?=	NUfwR5h6W0GQR1XS
NCI-H1838	NUDSSIZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mor1TWM2OD1zMj61NVUyKM7:TR?=	MnnqV2FPT0WU
Calu-6	M3vhOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGToNndKSzVyPUG0MlExOjFizszN	Mn7IV2FPT0WU
HCC70	M2\CdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnGUI1KSzVyPUG0MlQ2OSEQvF2=	M2XyPHNCVkeHUh?=
KARPAS-299	NEDGO3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFLqWlFKSzVyPUG1MlIyPTlizszN	MWHTRW5ITVJ?
CAL-27	NFLV[YtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYi5[5NwUUN3ME2xOU4{QDR\|IN88US=>	MmKxV2FPT0WU
NCI-H82	M37Zdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzyTWM2OD1zNT61N\|Ih\|ryP	NVnjVJdmW0GQR1XS
no-10	MmixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{Tz[2lEPTB;MUWuPVM5KM7:TR?=	M1vFSnNCVkeHUh?=
U251	Mn7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTF4LkO2O\|Uh\|ryP	MWfTRW5ITVJ?
TE-9	NFHGTppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGDCNllKSzVyPUG3MlUyPjZizszN	MofVV2FPT0WU
TE-10	NUPWNHJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzifnRKSzVyPUG5MlA3ODdizszN	NWfCO2JWW0GQR1XS
COLO-824	M1y2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LBUmlEPTB;MkCuPVI4PiEQvF2=	M2PWTXNCVkeHUh?=
HuP-T3	MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXLVR2o3UUN3ME2yNU4xPzR6IN88US=>	M1PW[XNCVkeHUh?=
KALS-1	NXXuVXR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvlTWM2OD1{MT6xO\|Uh\|ryP	MWPTRW5ITVJ?
L-428	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH:yOYhKSzVyPUKxMlQxOTZizszN	MXHTRW5ITVJ?
JAR	NVLYN205T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjS[5lVUUN3ME2yNU42ODJizszN	NVroWJdTW0GQR1XS
DoTc2-4510	MnTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{fZbWlEPTB;MkOuPFQ4PSEQvF2=	Ml;pV2FPT0WU
ABC-1	NYjvZZM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\LTWM2OD1{Nj63PVU4KM7:TR?=	M1r2W3NCVkeHUh?=
MHH-NB-11	MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTN\|LkO0OlQh\|ryP	NH7vSXpUSU6JRWK=
SW1463	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTN\|Lkm4N{DPxE1?	NHLYTIpUSU6JRWK=
SW1417	NVeyXZc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPjfGFpUUN3ME2zO{4xQTV{IN88US=>	M{XwS3NCVkeHUh?=
NB12	NUXTV2RlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrzRXRCUUN3ME2zPU41PjV3IN88US=>	NFX1UFdUSU6JRWK=
NY	NHzLUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTRzLkOyNFEh\|ryP	NIHkVoJUSU6JRWK=
H1048	MVLBdI9xfG:\|aYOgRZN{[Xl?	M{fvdFUxOCCwTR?=	M3XwS\|czKGh?		NXXtcXdDdmijbnPld{BCSlRvMk[z5qCUcW6mdXPl[EBieG:ydH;zbZM>	M13ZdFI2PzN5NUSy
H86	NE\rTlZCeG:ydH;zbZMhSXO\|YYm=	M33VS\|UxOCCwTR?=	MnfrO\|IhcA>?		Ml;YcohidmOnczDBRnQuOjZ\|4pETbY5lfWOnZDDhdI9xfG:\|aYO=	MkfRNlU4Ozd3NEK=
H196	M{HodWFxd3C2b4Ppd{BCe3OjeR?=	MYK1NFAhdk1?	NUfiSY5XPzJiaB?=		NHnMeFlvcGGwY3XzJGFDXC1{NkRihLNqdmS3Y3XkJIFxd3C2b4Ppdy=>	M{[0ZlI2PzN5NUSy
H446	M1j4O2Fxd3C2b4Ppd{BCe3OjeR?=	M4jCTFUxOCCwTR?=	M1TFeFczKGh?		M2Pnc45p[W6lZYOgRWJVNTJ4M,MAl4lv\HWlZXSgZZBweHSxc3nz	MUmyOVc{PzV2Mh?=
TFK-1	M3vNSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFy4bVU4OiCq	NHK5PJRFVVOR	M1\6bmlEPTB;NEegcm0>	MlzhNlUyPTJ{NES=
EGI-1	M3S3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYG3NkBp	MXPEUXNQ	NUnLNFhIUUN3ME21N{BvVQ>?	NEj6XYUzPTF3MkK0OC=>
OCI/AML3	M4PSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUewMlIh\|ryP	MXK0PEBp		MV3lcohidmOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGmwZIXj[YQh[nlic3XseY1mfGmwaXK=	NWnTXXliOjR5M{mzPVM>
U937	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M124d\|AvOiEQvF2=	MXO0PEBp		Morq[Y5p[W6lZYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCrbnT1Z4VlKGK7IIPlcJVu\XSrbnni	MYCyOFc{QTN7Mx?=
MOLM13	NFS3b3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYiwMlIh\|ryP	MVi0PEBp		M3vCOYVvcGGwY3XzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25iaX7keYNm\CCkeTDz[Yx2dWW2aX7pZi=>	NIOy[\|IzPDd\|OUO5Ny=>
MCF7	NUHmdWE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXtNlAhdk1?	NGPtW5k4OiCq	Mn7MSmJU	MV3y[YR2[2W\|IITo[UBRTUySMT3t[YRq[XSnZDDpcoNz\WG\|ZTDpckBk\WyuII\pZYJqdGm2eR?=	M4XaPVI1Pjh6MES2
TamR	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4D2cmlEPTB;MUlihKlvVQ>?	M4\tUVI1PDV5ME[5
MCF7-X	NFPDO49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1f0N2lEPTB;MkSgcm0>	NYPWXIJwOjR2NUewOlk>
T47D-tamR	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nHR2lEPTB;MUmgcm0>	Mn\CNlQ1PTdyNkm=
293T	M4XGW2Z2dmO2aX;uJGF{e2G7	M2H0fVIxKG6P	NFXRdmI{KGh?		NUnmSoJq\Gm\|coXweJMhSWu2LX3l[IlifGWmIGTJSk1KSSC\|dHHibYxqfHluIITyZY5{dG:lYYTpc44tKGGwZDDhZ5Rqfmm2eR?=	NHuyO4gzPDN4M{S0PS=>
SW620	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWj6[VI{OC5yMEGtNVDPxE1?	MUKyOEBp		M{PTXIlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iYYOgeIhmKGOxbnPlcpRz[XSrb36gdol{\XN?	NH;tTmMzPDN4M{S0PS=>
Huh7	NWTSVmtXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PWU\|UuOTByIH7N	MlXtNE0zPCCq	M2DicmROW09?	NXj1boZOcW6lcnXhd4V{KGOnbHyg[IVifGhiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{	NXzmR\|NrOjR{OUezNFA>
Hep3B	Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGX4eY02NTFyMDDuUS=>	Mln0NE0zPCCq	M4rZV2ROW09?	M37kRYlv[3KnYYPld{Bk\WyuIHTlZZRpKGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	MYqyOFI6PzNyMB?=
Huh7	MYDGeY5kfGmxbjDBd5NigQ>?	NVO1VFJyOTByIH7N	M3rr[VEzKGh?	NH:4eXJFVVOR	NY[4ZoxxcW6mdXPld{BifXSxcHjh[5nDqA>?	NVzPbZRROjR{OUezNFA>
U87-MG	NYTEPWMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2P1e\|czKGh?		MVnHTVUx6oDLPfMAjVc6KG6PwrC=	NUXSbHhyOjR{NEm2OFA>
L3.6pl	NUPLTXByT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfkenIyKM7:TR?=	MVy3NkBp		MlLubY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHPvcYJqdmWmIIfpeIghSk2VLUe3O\|YxPw>?	M{nKdlI1OjN\|M{m5
TE671	M3L5d2Fxd3C2b4Ppd{BCe3OjeR?=	NUXSR\|Q1OSEQvF2=	M17j[VQ5KGh?		NIPoRXBqdmO{ZXHz[ZMh[2WubDDhdI9xfG:\|aYOgbY5lfWOnZDDifUBCSlRvN{O3	NVrVelM1OjRzM{OyNVg>
RD	M3zVPGFxd3C2b4Ppd{BCe3OjeR?=	NHLJR5oyKM7:TR?=	NGnC[Wg1QCCq		MknVbY5kemWjc3XzJINmdGxiYYDvdJRwe2m\|IHnu[JVk\WRiYomgRWJVNTd\|Nx?=	NVexdHIyOjRzM{OyNVg>
RMS13	MWLBdI9xfG:\|aYOgRZN{[Xl?	M2rCXVEh\|ryP	MlrZOFghcA>?		M{TQPYlv[3KnYYPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JGFDXC15M{e=	MoKwNlQyOzN{MUi=
RH30	NXO5Xo1xSXCxcITvd4l{KEG\|c3H5	MkPsNUDPxE1?	MoPwOFghcA>?		NEG1ZnpqdmO{ZXHz[ZMh[2WubDDhdI9xfG:\|aYOgbY5lfWOnZDDifUBCSlRvN{O3	MlW2NlQyOzN{MUi=
Hep-2	MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYewMlAyNTFizszN	MkTWNVIuQTZiaB?=		NUPnW4VtcW6lcnXhd4V{KGOnbHyg[IVifGhiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{	NFe4cYYzPDFyM{e0PS=>
SCC-9	M{TMWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofMNE4xOS1zIN88US=>	NFv3VWYyOi17NjDo		MU\pcoNz\WG\|ZYOgZ4VtdCCmZXH0bEBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI>	MXSyOFExOzd2OR?=
Hep-2	M3T5WGZ2dmO2aX;uJGF{e2G7	M1T5UVAvOS9yLkWg{txO	Mkj4NlQhcA>?		MX3icI9kc3NibWTPVmMyKGGwZDDtWG9TSzJiYXP0bZZifGmxbh?=	M165bVI1OTB\|N{S5
SCC-9	MXPGeY5kfGmxbjDBd5NigQ>?	MoHhNE4yNzBwNTFOwG0>	NV;HWZNzOjRiaB?=		NETjN3RjdG:la4OgcXRQWkNzIHHu[EBuXE:UQ{KgZYN1cX[jdHnvci=>	NFfmbZkzPDFyM{e0PS=>
PANC-1	Ml[5RZBweHSxc3nzJGF{e2G7	M4Txe\|UxOCCwTR?=	M1jsWVQ5KGh?		NGfmWGd{\W6\|aYTpfoV{KHCjbnPy[YF1cWNiY3HuZ4VzKGOnbHzzJJRwKHKjZHnveIhmemGyeR?=	MlTWNlM5QDZ{OUS=
RMG2	NYXUdHFwSXCxcITvd4l{KEG\|c3H5	M3PTTlEuOTByMDDuUS=>	MUm3NkBp	NHO3fYlHSlN?	MX7pcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgZ49v[2WwdILheIlwdiCmZYDlcoRmdnSueR?=	MlvQNlM3OTV4M{G=
HAC2	NF7mdlZCeG:ydH;zbZMhSXO\|YYm=	MmO1NU0yODByIH7N	MX[3NkBp	MlfjSmJU	MlHybY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm=	M4DUWlI{PjF3NkOx
HT-29	M2rnOGFxd3C2b4Ppd{BCe3OjeR?=	NV;aXFhGOSEQvF2=	M3TGZ\|czKGh?		NUHsWVRF[XS2ZX71ZZRmeyB3LV\VMYlv\HWlZXSgZ4VtdCCmZXH0bC=>	MlPQNlE6PDlzMkG=
DLD1	MV\BdI9xfG:\|aYOgRZN{[Xl?	MnraNUDPxE1?	MYK3NkBp		NWD2SYZ3[XS2ZX71ZZRmeyB3LV\VMYlv\HWlZXSgZ4VtdCCmZXH0bC=>	MkmwNlE6PDlzMkG=
HT-29	MnfoSpVv[3Srb36gRZN{[Xl?	M4LufVEh\|ryP	NVHZNIVPPzJiaB?=		Mo\PbY5lfWOnczDheZRweGijZ4mgeI8h[2:wZnXyJIN6fG:ycn;0[YN1cW:w	M{P5dVIyQTR7MUKx
DLD1	NV[4R5RXTnWwY4Tpc44hSXO\|YYm=	NEjZPFAyKM7:TR?=	M4rjOVczKGh?		NVjYU\|kxcW6mdXPld{BifXSxcHjh[5khfG9iY3;u[oVzKGO7dH;wdo91\WO2aX;u	MVeyNVk1QTF{MR?=
Rh41	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIG3UGhKSzVyPUOwMlchdk1?	NYm4dIZ[OjF\|M{e2O\|k>
Rh18	Mm[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTRzLkSgcm0>	MXOyNVM{PzZ5OR?=
Rh30	NVTDNJhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHVTWM2OD1zNDDuUS=>	M1;SOVIyOzN5Nke5
BT-12	NH[zO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTJ2Lkegcm0>	NGG0[JczOTN\|N{[3PS=>
CHLA-266	MoC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vnRWlEPTB;MT6xJI5O	NX\NbItYOjF\|M{e2O\|k>
TC-71	NWDncI84T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWS3Z2x6UUN3ME20Ok42KG6P	MlnsNlE{Ozd4N{m=
CHLA-9	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF[5bpBKSzVyPUG1MlMhdk1?	M2qzd\|IyOzN5Nke5
CHLA-10	M17GO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\3TWM2OD1\|Lkmgcm0>	M2LRW\|IyOzN5Nke5
CHLA-258	NX3hepVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1HtUmlEPTB;MUCuOEBvVQ>?	NVXzfnZPOjF\|M{e2O\|k>
GBM2	M3TYZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnjITWM2OD12MD63JI5O	NGjVPYYzOTN\|N{[3PS=>
NB-1643	NELZPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLXTWM2OD1\|Mz64JI5O	MYWyNVM{PzZ5OR?=
NB-EBc1	NFL1bFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4P4cWlEPTB;MkeuNUBvVQ>?	Ml60NlE{Ozd4N{m=
CHLA-90	NIjCXWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\FSVZKSzVyPUO0MlUhdk1?	MVmyNVM{PzZ5OR?=
CHLA-136	NUnW[mV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzZXW5vUUN3ME2xOlIvPiCwTR?=	M2HrcFIyOzN5Nke5
NALM-6	M3q0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rlSWlEPTB;M{KuPUBvVQ>?	Ml;YNlE{Ozd4N{m=
COG-LL-317	NEfhbXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1P3T2lEPTB;MT6zJI5O	M4fXblIyOzN5Nke5
RS4;11	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDibJRIUUN3ME2zOUBvVQ>?	NF\Qc\|gzOTN\|N{[3PS=>
MOLT-4	M3PY[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF20U4RKSzVyPUiuOkBvVQ>?	M4fKNVIyOzN5Nke5
CCRF-CEM	MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13JVGlEPTB;ND6xJI5O	NWX5ZnhwOjF\|M{e2O\|k>
Kasumi-1	MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTFwNDDuUS=>	NV7jOGlSOjF\|M{e2O\|k>
Karpas-299	NV7CdY5{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYHyOVY6UUN3ME2yNU44KG6P	M2nBNVIyOzN5Nke5
Ramos-RA1	NVzw[5h1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\oTmlEPTB;OD6yJI5O	M{\DSlIyOzN5Nke5
H838	NGTRO2RHfW6ldHnvckBCe3OjeR?=	MXuxJO69VQ>?	Mn;6OFghcA>?		NXPIdXlScW6mdXPld{Bk\WyuIHH1eI9xcGGpeR?=	MnTBNlA{PjRzMUO=
H838	NF3NXYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnFOXJbOC1\|IN88US=>	NGHoT284OiCq		MmDubY5lfWOnczDndo94fGhiaX7obYJqfGmxbjDhcoQh[XW2b4DoZYd6	Mn;wNlAxOjh6NUS=
A549	NIHrcFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HuSFAuOyEQvF2=	MU[3NkBp		NXn2O5gycW6mdXPld{Boem:5dHigbY5pcWKrdHnvckBidmRiYYX0c5Bp[We7	NFrwfo8zODB{OEi1OC=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-mTOR / p-AKT / p-4EBP1 / p-P70S6K / p-PRAS40; PubMed: 24457069 Breast Cancer Res Western blots of 70% confluent TamR (A) and MCF7-X (B) cells treated for 15 minutes to 24 hours with AZD8055 (0 to 100 nM). Blots were probed with phospho- and total antibodies for mTORC1 and two signalling pathways. In both cell lines mTORC1 and mTORC2 s䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙 p-EGFR / EGFR; PubMed: 25654224 Int J Mol Sci PANC-1 cells were treated with AZD8055 for the indicated hours and EGFR (T/P), AKT (T/P) and ribosomal protein S6 (S6) (T/P) proteins were examined by western-blot; p-FOXO1 / FOXO1 / p-FOXO3a / FOXO3a ; PubMed: 25654224 Int J Mol Sci PANC-1 cells were transfected with FoxO1/FoxO3a siRNAs and treated with AZD8055 for 1 h, then AKT (T/P), FoxO1 (T/P), FoxO3a (T/P) and EGFR (T/P) proteins were examined by western-blot.	24457069 25654224
Immunofluorescence	p-4EBP1 / EIF4E / mTOR; PubMed: 24600487 Int J Clin Exp Med (C) Hoechst 33258 staining of Hep-2 cells after treatment with AZD8055 for 24 hours were shown. The cells were fixed and immunereacted with anti-mTOR antibody followed by incubation with Alexa 488-labeled secondary antibody (C-F). Images were taken by a c䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋à㺣痖�෋𢡄�෋䀷痗�෋౴�෋㵶痗�෋뺖᎒泌Itemｾ᎒Count﫨呂�෋猴፲�෋፲씢痗猸፲髸莤䥷堙᎒ｾ᎒�堞ﻮ᎒፲露𢡄堚،齃礤v�堞ﻮ᎒猢Wｾ᎒䨼Ą鹿齃殺獸W戀醙玛W戀ⶰ໯齃礤v 玚W玢Wⶰ໯﫰礌vtЉᔈැ鲬౴᥊疜犈፲Eo狜፲艘ᎂ艘ᎂ⩈̎䥠̌씢痗狠፲붖᎒i變ﱘ﫰﬐먙堘붖᎒狠፲i變ﱘ﫰먰堘ﱘ붖᎒�堞봆᎒릎堘붖᎒i꣩쯟巰痗ꣵ쯟巰痗Љ镴౴嶴痗Љ镨౴ᔈැ竗ᔈැ屷痗W竗尊痗 LC3B / p62 ; PubMed: 30337536 Cell Death Dis Immunofluorescence staining of U87 and U251 GICs, which treated by DMSO, AZD8055 (0.3 μM) and rapamycin (3 μM). The nuclei were stained with DAPI and the antibody against LC3B and p62. Images were captured by laser confocal microscope ( × 400), scale bar 䲧疝Ỵ疞	24600487 30337536
Growth inhibition assay	Cell viability ; PubMed: 29263324 Nat Commun Growth for the indicated cell lines was assessed after 72 h of treatment with AZD8055 (0–250 nM). Results are expressed as a percentage of cell number relative to the DMSO-treated control cells a.	29263324

体内研究

AZD8055 按2.5/10 mg/kg剂量作用于U87MG和A549移植瘤抑制pS6和pAKT，导致肿瘤生长受抑制。AZD8055按10/20 mg/kg剂量处理多种移植瘤包括U87MG, BT474c, A549, Calu-3, LoVo, SW620, PC3和MES-SA时，显示出明显的抗癌活性。^[1] AZD8055诱导肿瘤体积下降约40%, 伴随着AKT, S6K，和SGK蛋白激酶磷酸化的切除。用AZD8055 (5mg/kg, 每天2次) 和SAHA (100 mg/kg/每天)处理PTEN+/−LKB1+/hypo 移植瘤，导致肿瘤生长全部受抑制，且对鼠mTORC1和mTORC2信号抑制没有副作用。^[4]

激酶实验：^[1]	- 合并抑制mTOR的细胞为基础的测定实验: 通过高通量筛选细胞检测法，使用MDA-MB-468细胞，测定mTORC1 和mTORC2活性。用增加浓度的AZD8055处理细胞2小时。温育到最后时，细胞进行固定，冲洗，用p-Akt（S473）抗体和p-S6（S235/236)抗体探测。用激光扫描仪检测磷酸化水平。
细胞实验：^[1]	- 合并 Cell lines: U87MG, A549，和H838 细胞 Concentrations: 溶解在DMSO中，作为10 mM 储备液, 0.001-1.0 μM Incubation Time: 72到96小时 Method: 用AZD8055处理细胞72到96小时，用0.03 mg/mL Hoechst 33342染色细胞核，用1 μg/mL 吖啶橙染色酸性小囊泡染色。通过ArrayScan II平台在450和536纳米处获得图像，测量酸性小囊泡的百分数和细胞数量。进行LC3测评，用10 μg/mL e64d/抑肽素处理细胞30 到90分钟，然后和AZD8055温育。细胞溶解在冰上，通过免疫印迹法分析。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: U87MG, BT474c, A549, Calu-3, LoVo, SW620, PC3 and MES-SA U87-MG和A549细胞建立在无病原体，雌性裸鼠体内(nu/nu:Alpk)。 Dosages: 2.5-20 mg/kg Administration: 口服饲喂，每天1到2次。 (Only for Reference)

参考文献

[4] García-Martínez JM, et al. Br J Cancer, 2011, 104(7), 1116-1

- 合并

溶解度 (25°C)

体外	DMSO	50 mg/mL warmed (107.4 mM)
	Ethanol	3 mg/mL (6.44 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 4% DMSO+30% PEG 300+ddH2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download AZD8055 SDF

分子量	465.54
化学式	C₂₅H₃₁N₅O₄
CAS号	1009298-09-2
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

选择性强的mTOR抑制剂

Rapamycin (Sirolimus) : mTORC1-selective, IC50=~0.1 nM.
活性最高的mTOR抑制剂

Rapamycin (Sirolimus) : mTOR, IC50=~0.1 nM.
FDA批准的mTOR抑制剂

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
最新的mTOR抑制剂

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

研究领域

产品类型

定制您的化合物库

AZD8055

客户使用Selleck生产的AZD8055发表文献171篇：

产品安全说明书

mTOR抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download AZD8055 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

相关mTOR产品